ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $3.53 billion. The enterprise value is $4.15 billion.
Market Cap | 3.53B |
Enterprise Value | 4.15B |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 673.95 million shares outstanding. The number of shares has increased by 27.19% in one year.
Shares Outstanding | 673.95M |
Shares Change (YoY) | +27.19% |
Shares Change (QoQ) | +2.06% |
Owned by Insiders (%) | 79.62% |
Owned by Institutions (%) | 8.85% |
Float | 145.27M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5,677.67 |
Forward PS | 357.69 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 6,667.50 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.05
Current Ratio | 5.05 |
Quick Ratio | 4.61 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -3.51 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -148.40% |
Return on Capital (ROIC) | -122.73% |
Revenue Per Employee | $990 |
Profits Per Employee | -$928,656 |
Employee Count | 628 |
Asset Turnover | 0.00 |
Inventory Turnover | n/a |
Taxes
Income Tax | -40,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +137.10% in the last 52 weeks. The beta is 0.04, so ImmunityBio's price volatility has been lower than the market average.
Beta (1Y) | 0.04 |
52-Week Price Change | +137.10% |
50-Day Moving Average | 5.10 |
200-Day Moving Average | 3.36 |
Relative Strength Index (RSI) | 47.91 |
Average Volume (30 Days) | 4,160,085 |
Short Selling Information
The latest short interest is 54.77 million, so 8.13% of the outstanding shares have been sold short.
Short Interest | 54.77M |
Short Previous Month | 53.25M |
Short % of Shares Out | 8.13% |
Short % of Float | 37.70% |
Short Ratio (days to cover) | 12.86 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $622,000 and -$583.20 million in losses. Loss per share was -$1.15.
Revenue | 622,000 |
Gross Profit | 622,000 |
Operating Income | -362.25M |
Pretax Income | -583.24M |
Net Income | -583.20M |
EBITDA | -429.41M |
EBIT | -454.04M |
Loss Per Share | -$1.15 |
Balance Sheet
The company has $266.46 million in cash and $882.14 million in debt, giving a net cash position of -$615.68 million or -$0.91 per share.
Cash & Cash Equivalents | 266.46M |
Total Debt | 882.14M |
Net Cash | -615.68M |
Net Cash Per Share | -$0.91 |
Equity / Book Value | -586.99M |
Book Value Per Share | -0.87 |
Working Capital | 235.80M |
Cash Flow
In the last 12 months, operating cash flow was -$366.76 million and capital expenditures -$30.58 million, giving a free cash flow of -$397.34 million.
Operating Cash Flow | -366.76M |
Capital Expenditures | -30.58M |
Free Cash Flow | -397.34M |
FCF Per Share | -$0.78 |
Margins
Gross margin is 100.00%, with operating and profit margins of -58,239.55% and -93,761.41%.
Gross Margin | 100.00% |
Operating Margin | -58,239.55% |
Pretax Margin | -93,767.85% |
Profit Margin | -93,761.41% |
EBITDA Margin | -69,037.62% |
EBIT Margin | -72,996.46% |
FCF Margin | -63,881.19% |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -27.19% |
Shareholder Yield | -27.19% |
Earnings Yield | -16.51% |
FCF Yield | -11.25% |
Analyst Forecast
The average price target for ImmunityBio is $5.00, which is -4.58% lower than the current price. The consensus rating is "Hold".
Price Target | $5.00 |
Price Target Difference | -4.58% |
Analyst Consensus | Hold |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -8.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -8.68 |
Piotroski F-Score | 3 |